Turn8 Private Wealth Inc. Makes New $1.03 Million Investment in Abbott Laboratories $ABT

Turn8 Private Wealth Inc. acquired a new stake in Abbott Laboratories (NYSE:ABT) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the healthcare product maker’s stock, valued at approximately $1,027,000.

A number of other large investors have also made changes to their positions in the stock. Syntegra Private Wealth Group LLC increased its position in Abbott Laboratories by 1.9% during the 1st quarter. Syntegra Private Wealth Group LLC now owns 12,736 shares of the healthcare product maker’s stock worth $1,308,000 after purchasing an additional 237 shares in the last quarter. HB Wealth Management LLC lifted its holdings in Abbott Laboratories by 1.3% in the 1st quarter. HB Wealth Management LLC now owns 179,588 shares of the healthcare product maker’s stock valued at $18,438,000 after purchasing an additional 2,317 shares in the last quarter. Plimoth Trust Co. LLC boosted its stake in shares of Abbott Laboratories by 6.3% during the 1st quarter. Plimoth Trust Co. LLC now owns 27,427 shares of the healthcare product maker’s stock worth $2,816,000 after purchasing an additional 1,621 shares during the last quarter. Osborne Partners Capital Management LLC boosted its stake in shares of Abbott Laboratories by 4.3% during the 1st quarter. Osborne Partners Capital Management LLC now owns 112,500 shares of the healthcare product maker’s stock worth $11,550,000 after purchasing an additional 4,596 shares during the last quarter. Finally, PFG Investments LLC grew its holdings in shares of Abbott Laboratories by 2.7% during the first quarter. PFG Investments LLC now owns 17,297 shares of the healthcare product maker’s stock worth $1,776,000 after buying an additional 452 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $95.25 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a 50 day moving average price of $88.95 and a 200 day moving average price of $104.35. The company has a market cap of $165.91 billion, a price-to-earnings ratio of 26.68, a PEG ratio of 1.64 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the firm posted $1.09 earnings per share. Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Insider Transactions at Abbott Laboratories

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ABT. UBS Group reduced their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Evercore cut their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Weiss Ratings cut Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Jefferies Financial Group lowered their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Mizuho dropped their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.42.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.